Head-to-Head Comparison of Two Popular Cortical Thickness Extraction Algorithms: A Cross-Sectional and Longitudinal Study

Alberto Redolfi1*, David Manset2, Frederik Barkhof3, Lars-Olof Wahlund4, Tristan Glatard5,6, Jean-François Mangin7, Giovanni B. Frisoni1,8, neuGRID Consortium, for the Alzheimer’s Disease Neuroimaging Initiative

1 Laboratory of Epidemiology & Neuroimaging, IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy, 2 Gnúbila France, Imp Pres d’en Bas, Argonay, France, 3 Department of Radiology, VU University Medical Center, Amsterdam, The Netherlands, 4 Department of Neurobiology, Caring Sciences & Society, Division of Clinical Geriatrics Novum, Karolinska Institutet, Stockholm, Stockholm, Sweden, 5 CREATIS, CNRS, INSERM, University of Lyon, Lyon, France, 6 McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada, 7 CATI, Neurospin, CEA, GIF/YVETTE, France, 8 Laboratory of Neuromaging of Aging, Memory Clinic and LANVIE, University Hospitals and University of Geneva, Geneva, Switzerland

* aredolfi@fatebenefratelli.it

Abstract

Background and Purpose

The measurement of cortical shrinkage is a candidate marker of disease progression in Alzheimer’s. This study evaluated the performance of two pipelines: Civet-CLASP (v1.1.9) and FreeSurfer (v5.3.0).

Methods

Images from 185 ADNI1 cases (69 elderly controls (CTR), 37 stable MCI (sMCI), 27 progressive MCI (pMCI), and 52 Alzheimer (AD) patients) scanned at baseline, month 12, and month 24 were processed using the two pipelines and two interconnected e-infrastructures: neuGRID (https://neugrid4you.eu) and VIP (http://vip.creatis.insa-lyon.fr). The vertex-by-vertex cross-algorithm comparison was made possible applying the 3D gradient vector flow (GVF) and closest point search (CPS) techniques.

Results

The cortical thickness measured with FreeSurfer was systematically lower by one third if compared to Civet’s. Cross-sectionally, FreeSurfer’s effect size was significantly different in the posterior division of the temporal fusiform cortex. Both pipelines were weakly or mildly correlated with the Mini Mental State Examination score (MMSE) and the hippocampal volumetry. Civet differed significantly from FreeSurfer in large frontal, parietal, temporal and occipital regions (p<0.05). In a discriminant analysis with cortical ROIs having effect size larger than 0.8, both pipelines gave no significant differences in area under the curve (AUC). Longitudinally, effect sizes were not significantly different in any of the 28 ROIs.
tested. Both pipelines weakly correlated with MMSE decay, showing no significant differences. Freesurfer mildly correlated with hippocampal thinning rate and differed in the supramarginal gyrus, temporal gyrus, and in the lateral occipital cortex compared to Civet (p < 0.05). In a discriminant analysis with ROIs having effect size larger than 0.6, both pipelines yielded no significant differences in the AUC.

Conclusions

Civet appears slightly more sensitive to the typical AD atrophic pattern at the MCI stage, but both pipelines can accurately characterize the topography of cortical thinning at the dementia stage.

Introduction

Structural imaging has had a long role as biomarker of progression among entry criteria for AD trials [1]. The advent of disease-modifying therapies has led to interest in the use of magnetic resonance imaging (MRI) as a possible “surrogate” measure of outcome. The two most established markers of progression on MRI are the hippocampal and the whole brain atrophy rates [2]. However, the first study assessing the effects of β-amyloid immunotherapy reported surprising findings, i.e. greater hippocampal and whole-brain atrophy rates in patients treated with AN1792 vaccination [3]. On the contrary, cortical thickness might be a promising “global” measure of disease progression, as it could represent a marker more specifically related to the evolution of AD evolution [4,5] and might be useful to evaluate the efficacy of new disease-modifying therapies [6].

Several tools for the automatic extraction of cortical thickness have been developed, each based on different levels of complexity, robustness, and automation. Among others, the Civet-CLASP pipeline [7] and Freesurfer [8] are the two most exploited algorithms within the neuroscientific community. Obtaining an accurate thickness measurement requires the explicit reconstruction of the outer boundary on the base of the inner boundary [9], which can be done along two different approaches: (I) a skeleton method or (II) a model-based deformation of the inner surface. CIVET makes use of the skeleton mesh-based approach called constrained Laplacian anatomic segmentation using proximity. The pial surface is expanded from the white surface up to the boundary between gray matter and CSF, along a Laplacian map [10]. Terms for stretch and self-proximity are included to regularize the deforming mesh and avoid mesh self-intersection inside sulci. Differently, Freesurfer makes use of iterative and adaptive deformation and segmentation methods, deforming the mesh to reconstruct the inner and the pial surfaces. Freesurfer uses a routine function to find and correct the topological defects in the initial inner surface. The deformable model is constrained by a second-order smoothing term [11] and by a mesh self-intersection prevention routine [8], which both help to correctly establish the boundaries between adjacent banks in tight sulci. Unfortunately, some relevant problems hamper the use of these techniques. Both tools measure the cortical thickness from two 3D cortical sheets, each of which is composed by thousands of vertices and faces, making the reconstruction of the cortical mantle a complex and time consuming procedure [12].

Although several methods have been proposed in the past decades, little work has been done to compare their performances on real clinical datasets [13]. The aim of this study was to perform a head-to-head comparison between Civet-CLASP and Freesurfer. This can be considered a mandatory step toward the standardization of cortical thickness biomarkers, which in
turn will pave the way to effectively translate a three-dimensional cortical marker to innovative disease modifying trials.

**Materials and Methods**

**Subjects**

The sample group we selected consisted of 185 subjects (69 normal elderly controls (CTR), 37 stable MCI (sMCI), 27 progressive MCI (pMCI), and 52 Alzheimer (AD) patients), belonging to the Alzheimer’s Disease Neuroimaging Initiative (ADNI1). Demographics and clinical data are summarized in Table 1. MMSE and CDR scores differed significantly among the four groups (P < 0.001), while age and educational levels were not significantly different. There was a significant difference in sex (P < 0.002) with a higher prevalence of male. Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database. As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. ADNI1 study is conducted in accordance with the Good Clinical Practice guidelines, the Declaration of Helsinki, and U.S. 21 CFR Part 50 (Protection of Human Subjects), and Part 56 (Institutional Review Boards). ADNI1 study was approved by the Institutional Review Boards (IRB) of all of the participating institutions. Specifically, they are: Albany Medical College, Banner Alzheimer’s Institute, Baylor College of Medicine, Boston University, Brigham and Women’s Hospital, Butler Hospital Memory & Aging Program, Case Western Reserve University, Cleveland Clinic, Columbia University, Dartmouth—Hitchcock Medical Center, Dent Neurologic Institute, Duke University Medical Center, Emory University, Georgetown University, Howard University, Indiana University, Jefferson Hospital for Neuroscience, Johns Hopkins University, Mayo Clinic, Jacksonville, Mayo Clinic, Rochester, McGill University/Jewish General Hospital Memory Clinic, Medical University of South Carolina, Mount Sinai School of Medicine, Neurological Care of Central New York, New York University Medical Center, Northwestern University, Ohio State University, Olin Neuropsychiatry Research Center, Oregon Health and Science University, Parkwood Hospital, Premiere Research Institute, Rhode Island Hospital, Rush University Medical Center, Saint Joseph’s Health Center, Stanford

|   | CTR | sMCI | pMCI | AD | P   |
|---|-----|------|------|----|-----|
| **Number** | 69  | 37   | 27   | 52 |     |
| **Age (y)** | 75.6 ± 4.8 | 74.6 ± 7.5 | 73.1 ± 8 | 76.0 ± 6.2 | N.S. |
| **Education (y)** | 15.9 ± 2.9 | 15.6 ± 3.3 | 16.6 ± 2.1 | 15.0 ± 2.6 | N.S. |
| **Gender (M/F)** | 38/31 | 22/15 | 17/10 | 27/25 | <0.002 |
| **MMSE (BSL)** | 29.2 ± 1.0 | 27.4 ± 2.0 | 27.1 ± 1.7 | 23.4 ± 2.3 | <0.001 |
| **Δ MMSE** | 0.1 ± 1.4 | -0.4 ± 1.8 | -3.4 ± 3.6 | -3.9 ± 5.1 | <0.001 |
| **CDR** | 0 (69) | 0.5 (37) | 0.5 (27) | 0.5 (27)-1 (25) | <0.001 |
| **ApoE ε4 carriers (%)** |   |   |   |   |
| -/- | 66.5 | 35 | 40.5 | 31 |
| -/+ | 28  | 60 | 44.5 | 50 |
| +/+ | 5.5 | 5 | 15 | 19 |

Data are expressed as mean value ± standard deviation (σ). BSL: Baseline; Δ: Difference between month 24 and baseline; MMSE: Mini Mental State Examination scores; CDR: Clinical Dementia Ratings score; CTR: Controls; sMCI: stable MCI; pMCI: progressive MCI; AD: Alzheimer’s Disease; P: significance on Fisher’s exact test or ANOVA; N.S.: not significant.

doi:10.1371/journal.pone.0117692.t001
University, Banner Sun Health Research Institute, Sunnybrook Health Sciences, University of Alabama, Birmingham, University of British Columbia, University of California, Davis, University of California, Irvine, University of California, Irvine-BIC, University of California—Los Angeles, University of California—San Diego, University of California—San Francisco, University of Kansas, University of Kentucky, University of Michigan, Ann Arbor, University of Nevada School of Medicine, Las Vegas, University of Pennsylvania, University of Pittsburgh, University of Rochester, University of Southern California, University of Texas Southwestern Medical Center, University of Wisconsin, Wake Forest University, Washington University St. Louis, Wein Center for Clinical Research and Yale University School of Medicine. Informed written consent was obtained from all participants at each site. A detailed description of the study procedures, IRB approval and informed written consents is available at http://www.adni-info.org/pdfs/adni_protocol_9_19_08.pdf (section D.5). Data used in this analysis were downloaded from the ADNI database (http://adni.loni.usc.edu/). List of subjects’ RIDs can be found in S1 Table.

Research infrastructures and pipelines

The evaluation of the cortical thickness is a computationally demanding task. We used two online e-infrastructures, namely neuGRID (https://neugrid4you.eu) [14] and VIP (http://vip.creatis.insa-lyon.fr) [15] to massively distribute job analyses, thus reducing the overall processing. Civet’s and Freesurfer’s main features are summarized as follow:

- Civet-CLASP uses an iterative morphing method and intensity non-uniformity correction; spatial normalization to stereotaxic space; tissue classification; cortical surface extraction; cortical thickness measurement. The correspondence among subjects is granted by the non-linear registration of the sulcal geodesic depth map with an average sulcal depth sphere surface [10].

- Freesurfer uses iterative adaptive morphing/segmentation methods and relies on similar preprocessing steps, although differently arranged. The white matter derives from the segmentation and topology correction. Gray matter is derived along T1 intensity gradient. Correspondence among subjects is obtained through surface registration to the Freesurfer reference atlas. In this study, we used the longitudinal processing stream, where the variability is reduced using repeated measures from the same subject (i.e.: baseline, month 12 (data not shown), and month 24 cross-sectional analyses) as common information to initialize the process [16].

Table 2 reports the main features of the two pipelines.

Study design

The workflow of the study is reported as supplementary figure (see S1 Fig.).

MRI acquisition

The Alzheimer’s Disease Neuroimaging Initiative (ADNI) has a specific protocol for the acquisition and harmonization of MR images. The ADNI 3D T1-weighted structural images are acquired using selected systems from GE Healthcare, Philips Medical Systems and Siemens Medical Solutions, with an eye toward minimizing cross-platform differences. The Magnetization Prepared RApid Gradient Echo (MPRAGE) acquisition sequence has nominal T1 = 1000 ms, TR = 2400 ms and TE = 5 ms. The B2B acquisition set in ADNI1 is composed of a MPRAGE scan and a MPRAGE-repeat scan.
| FEATURES                  | CIVET                                      | FREESURFER                                                                 |
|--------------------------|--------------------------------------------|-----------------------------------------------------------------------------|
| MRI input file format    | MINC                                       | DICOM; NIFTI                                                                |
| Mesh output format       | MNI OBJ                                    | PIAL                                                                       |
| 3D mesh generation       | Iterative morphing method (i.e.: skeleton-based reconstruction). The pial surface is expanded from the white surface to the boundary between gray matter and CSF along a Laplacian map | Iterative adaptive morphing and segmentation methods (i.e.: model-based deformation of the inner surface) |
| 3D mesh pitfalls         | Requiring corrections for topological errors | Affected by geometric inaccuracies                                           |
| Sensitivity to artifacts | Variation of the signal intensity across the image; shading artifacts; intensity non-uniformity (through N3 procedure); poor radio frequency field uniformity, and eddy currents are mitigated | Motion correction (when there are multiple MR source volumes of the same subject) and non-uniform intensity normalization in MR data (through N3 procedure) are carried out |
| Cortex representation    | Geometrically accurate                      | Topologically correct                                                      |
| Longitudinal stream      | Option not available                        | Option available. Freesurfer, during the longitudinal stream, through repeated cross-sectional measures from the same subject reduces the variability of the cortical thickness estimation. In the present study the longitudinal stream has been used (i.e.: baseline, month 12, and month 24) |
| Computational time       | 7 hours per single subject                  | 35 hours per single subject                                                 |
| Intra-algorithm thickness repeatability | (no differences between MPRAGE and MPRAGE repeat FDR corrected p-maps) | (no differences between MPRAGE and MPRAGE repeat FDR corrected p-maps) |
| Number of vertices on the cortical surface | ICO6                                        | ICO7                                                                       |
| Max image voxel resolution as input | 0.5 x 0.5 x 0.5 mm³ | 1.0 x 1.0 x 1.0 mm³ |
| Average thickness        | 1 mm thicker than Freesurfer in all the diagnostic groups and in all time points (baseline and month 24) | 1 mm thinner than Civet in all the diagnostic groups and in all time points (baseline and month 24) |
| Strengths                | CROSS-SECTIONAL                            | CROSS SECTIONAL                                                            |
|                          | 1) Constant thinning progression in different disease stages | 1) Thinning progression peaks earlier than Civet                           |
|                          | 2) Weak to medium trend of correlation to both MMSE score and hippocampal volume | 2) Slightly higher disease effect (Hedge’s g) in comparing CTR with pMCI and AD |
|                          | 3) Sensitive in expected cortical regions affected by disease neuropathology (i.e.: cingulate, dorsolateral frontal and parietal cortex) | 3) Higher, but not significant, AUC to discriminate CTR versus pMCI or AD |
|                          | LONGITUDINAL                               | LONGITUDINAL                                                                |
|                          | 1) Higher disease effect in pMCI and AD | 1) Higher disease effect trend in CTR                                       |
|                          | 2) More sensitive to significant atrophic patterns in fronto-parietal regions (especially in pMCI) | 2) Better correlation with hippocampal volumetric atrophy                  |
|                          | 3) Sensitive to detect statistical significant atrophic differences between: AD vs CTR; AD vs sMCI; pMCI vs CTR | 3) Sensitive to detect statistical significant atrophic differences between: AD vs CTR; AD vs sMCI |
|                          | 4) Sensitive enough to detect statistical significant atrophic differences in many temporal ROIs between: sMCI vs pMCI | 4) Higher, but not significant, AUC to discriminate pMCI due to AD in a time span of 2 years |
| Algorithm Validations    | Manual method of tagging GM/CSF and GM/WM interfaces of forty brains on twenty regions of interest of young healthy volunteers (Kabani et al. 2001) | Comparison against post-mortem subjects with Huntington Disease and healthy control (Rosas et al. 2002) both of 43 years old |

Comparative table where the main characteristics of the pipelines involved in this head-to-head comparison are summarized. MINC: Medical Imaging Network Common Data Form; DICOM: Digital Imaging and Communications in Medicine; NIFTI: Neuroimaging Informatics Technology Initiative; MNI OBJ: geometry file format developed by the Montreal Neurological Institute; PIAL: geometry file format developed by Martinos Center for Biomedical Imaging.

doi:10.1371/journal.pone.0117692.t002
Visual quality control

All the post-processed scans output by neuGRID and VIP were quality controlled by an expert evaluator, who visually inspected them using the Matlab Imaging toolbox for 3D surfaces, which enables the user to rotate, zoom in and out the cortical surface along all the possible orientations. A reconstructed mesh was judged accurate when all the following 23 Sulci were visible and correctly reconstructed: (I) Sylvian Fissure, (II) Central Sulcus, (III) Postcentral Sulcus, (IV) Precentral Sulcus, (V) Superior Temporal Sulcus, (VII) Intraparietal Sulcus, (VIII) Primary Intermediate Sulcus, (IX) Secondary Intermediate Sulcus, (X) Transverse Occipital Sulcus, (XI) Inferior Temporal Sulcus, (XII) Inferior Frontal Sulcus, (XIV) Olfactory Sulcus, (XV) Occipital-Temporal Sulcus, (XVI) Collateral Sulcus, (XVII) Olfactory Control Line, (XVIII) Olfactory-Middle Frontal Control Line, (XIX) Middle Frontal-Precentral Control Line, (XX) Precentral-Central Control Line, (XXI) Central-Postcentral Control Line, (XXII) Postcentral-Transverse Occipital Control Line and (XXIII) Occipital Control Line. As a result of this visual QC, only one of the two B2B cortical surfaces was chosen for analyses.

Hybrid Template Generation enabling head-to-head (H2H) comparison

Cortex surfaces as extracted by Civet and Freesurfer are morphologically and topographically different. For an accurate comparison to be possible, it was necessary to deform the surface morphology of at least one algorithm. To map each point of one surface onto the other, we adopted an elastic non-rigid registration to get the right displacement vector. To our knowledge, Gradient Vector Flow (GVF) has not been used before to control 3D free form deformation. The vector field computed via GVF provided the directions along which each vertex of our source surface could evolve to match a corresponding point on the target surface. Once registered, space coordinates of each face vertices are coincident and vertices are spatially aligned. Subsequently, in order to compare the correct cortical index value at each vertex, we adopted the Closest Point Search (CPS) technique, essential to establish the correct topographical match of the same morphological points obtained with 3D GVF. For each point, CPS returned the mutual match between Civet’s and Freesurfer’s cortical thickness array. The entire process enabling the head-to-head comparison is illustrated in Fig. 1. The procedure was implemented using Matlab (v2009b). The data generated in this study are made publicly available to promote the evaluation of cortical thickness tool (https://neugrid4you.eu/datasets).

Atlases and ROIs Definition

The head-to-head comparison and the ROI analyses between pipelines were done using the Harvard-Oxford cortical structural atlas. We chose 28 out of the 48 cortical areas provided [17], consistently with those used by other reference work groups [18–21]. For a complete list of the selected ROIs, see Table 3.

Statistical analysis to compare Cortical Thinning patterns

Cortical thinning within the same diagnostic groups was assessed using paired samples t-tests. P-maps were corrected for multiple comparisons using the False Discovery Rate (FDR; \(\alpha = 0.01\)) method [22]. Tukey-Kramer post-hoc testing of ANOVA (\(\alpha = 0.05\) in cross sectional comparison and \(\alpha = 0.01\) in longitudinal analysis) was used to test thinning differences among the diagnostic groups and the different ROIs analyzed. Effect sizes were computed as Hedge’s g and Z-tests were performed to assess significant discrepancies between the performances of each pipeline. Correlations of cortical thickness to MMSE scores and hippocampal volumes were investigated, Steiger’s Z was used to assess significant differences between Pearson’s r
values. Logistic regressions were applied on pre-selected thickness ROIs, and Receiver Operating Characteristic (ROC) curves were used to assess discriminative accuracy of the two pipelines. AUCs were statistically compared using the method adopted by Hanley and McNeil [23], setting the threshold for significance at a $p$ value of 0.05. Kendall’s tau coefficients were calculated and the derived z-test converted into the Pearson’s correlation coefficient. Statistical analysis was performed with Matlab (v2009b).

Cortical Metrics

Both pipelines define thickness as the Euclidean distance and both can produce maps not restricted to the original MRI voxel resolution: thus, they can detect sub-millimeter differences between and within groups [8,24]. For the sake of this article, we defined the concept of “disease effect” as the relative predominance of one pipeline over the other to detect atrophy when comparing two groups (G) or two time-points (T):

$$DISEASE\text{EFFECT}\{\Delta G|\Delta T\} = (\Delta_{FS}^T \text{ Thickness} - \Delta_{CV}^T \text{ Thickness})$$

The values of the disease effect are mapped vertex by vertex on the hybrid template previously created (see Figs. 2 and 3 panel b).
Results

Comparison of cortical metrics

The reconstruction of cortical thickness from B2B scans provided identical outcomes within the same pipeline (see S2 Fig.).

Compared to Civet, Freesurfer provided absolute values systematically lower by about 30% (see S3 Fig.). The difference between Civet and Freesurfer with respect to between-subjects variability (CoV) [25] ranges between 17–26% in the different diagnostic groups. The whole cortical thickness value at baseline and at month 24 is reported as S2 Table; both Civet and Freesurfer were found to provide identical outcomes within the same pipeline (see S2 Table).
Freesurfer showed increasing values of thinning rates with the progression of the pathology. The relative percentage of thinning in paired diagnostic groups at baseline is reported as S3 Table; no statistical differences among the groups were detected in neither pipelines. The percentage of longitudinal thinning rate across the four different diagnostic groups is reported as S4 Table; both pipelines detected differences between AD versus CTR, and between AD versus sMCI; moreover, Civet was able to detect a significant longitudinal thinning difference between pMCI versus CTR.

Cross-sectional and longitudinal thinning differences between Civet and Freesurfer

Fig. 2 compares CTR with sMCI, pMCI, and AD at baseline, and shows the details of the differences between Civet and Freesurfer at the individual vertex level. Fig. 3 compares, for each diagnostic group, the longitudinal (2 years) cortical thinning rate at the individual vertex level as computed by Civet and Freesurfer.

ROI Analysis

Table 3 represents the comparison of the cross-sectional thickness differences at baseline, while Table 4 represents the longitudinal thinning rates with respect to the 28 selected ROIs. Cross-sectionally, the multiple comparison procedure highlighted small differences. Civet indicated as significant the temporal planum ROI, while Freesurfer identified as significant the superior parietal lobe. Longitudinally, Civet appeared to be much more sensitive in detecting significant thinning rate differences between CTR and AD in all the 28 ROIs considered, as opposed to only 22 ROIs as detected by Freesurfer (check symbol ¥). Comparing sMCI to AD, Civet was able to detect significant longitudinal thinning rate changes in all the 28 ROIs, compared to only 7 ROIs in Freesurfer (check symbol ◇). Again, Civet was able to detect significant longitudinal thinning rate changes between CTR and pMCI in 18 ROIs, as opposed to only 10 ROIs in Freesurfer (check symbol ◊). Lastly, Civet detected significant longitudinal thinning rate changes also between sMCI and pMCI in 10 ROIs (check symbol ◐) while Freesurfer could not find any variations. P values for multiple comparisons were always more significant in Civet (P < 0.0001).

Effect sizes

The effect sizes were derived as the Hedge’s g (Fig. 4). In the cross-sectional analysis, we decided to represent only CTR versus pMCI and versus AD, being these the combinations of highest interest when defining populations for disease-modifying and clinical trials. The effect size was always above 0.8 in those cortical regions expected to be heavily affected by the disease neuropathology. In CTR versus pMCI, Freesurfer’s effect size was always higher. Only the posterior division of the temporal fusiform cortex was found to be statistically different (p<0.05) between the two pipelines. In CTR versus AD, the Hedge’s g values followed the same trend for both algorithms without any statistical difference.

Longitudinally, Hedge’s g trends were pretty similar for the two algorithms and increasing with the disease progression. No statistical differences were found in any ROIs or groups.

Cortical thickness versus cognitive impairment and hippocampal volumetry

Pearson’s r correlation coefficients of regional cortical thickness with MMSE scores and quantitative hippocampal volume measurements (NeuroQuant—[26]) were investigated in each
Fig 2. Cross-sectional comparison. A) Absolute difference maps (mm) in Freesurfer and Civet. The degree of atrophy ranges between 0.1 and 0.7 mm in the different areas of the cortical mantle. B) Disease effect maps. There is a consistent delta ($\pm0.3$ mm) among the compared groups. Negative value means higher disease effect for Freesurfer (i.e.: parietal-temporal and precuneus areas); positive value means higher disease effect for Civet (i.e.: association areas and limbic parts of the cortex). C) Statistical difference maps ($p<0.01$ FDR-corrected). No significant voxels were found comparing CTR to sMCI. Atrophic areas were found contrasting pMCI with CTR (i.e.: the posterior cingulate, temporal lobe and frontal gyrus) with both tools. Comparing CTR versus AD the
ROI (see Fig. 5 panels A and B) within the CTR and pMCI patients, which represent the most appropriate population for innovative clinical trial designs.

In the CTR group, the relationship between pipelines’ cortical thickness and cognitive function or hippocampal atrophy was generally weak (-0.2 < r < 0.2), cross-sectionally and longitudinally. This was expected due to the absence of the disease in these completely asymptomatic subjects. However, significant differences between Civet and Freesurfer were found in few areas (i.e.: frontal, parietal, occipital, and temporal).

In pMCI, the product momentums grew up to a medium and high levels (-0.27 < r < 0.64) especially for some expected ROIs, such as: precuneus cortex, cingulate and parahippocampal gyri. Significant differences between Civet and Freesurfer were found in a number of ROIs (i.e.: frontal, parietal, occipital, limbic, and temporal). Both Civet and Freesurfer cortical thickness measurements correlate better with hippocampal atrophy measurements than with neuropsychological tests.

ROC Analysis

Fig. 6 shows the Receiver Operating Characteristic (ROC) curves used to discriminate pMCI and AD patients from the CTR group at baseline, together with the longitudinal cortical pattern used to discriminate pMCI. Identifying the most informative ROI was mandatory to reduce the dimensionality problem. In order to maximize the discriminatory power, we adopted a sequential forward search strategy (i.e., adding successive ROIs to the target set) as feature selection criterion. The goal was to find the best combination of ROIs for both tools with the highest discriminatory power. The best ROIs used to generate the final ROCs were different in each curve and for each algorithm. We started selecting those ROI with the highest effect size; at each further step, we assessed other ROIs with a medium-large effect size (d > 0.8 in cross sectional analysis; d > 0.6 in longitudinal analysis). This process reduced the inherent noise of high-resolution data, as well as the risk of over-fitting. Logistic regressions on regional cortical thickness in the selected combinations of ROIs were performed to build ROC curves, AUCs and the relative Intervals of Confidence (CI). No statistical difference (p>0.05) was found between the AUCs derived with Civet and those derived with Freesurfer. At baseline, CTR versus pMCI yielded 0.8953 and 0.9313 (z = -0.46, r = 0.31), while CTR versus AD yielded 0.9568 and 0.9677 respectively (z = -0.38, r = 0.46). In the longitudinal framework, pMCI yielded 0.7503 and 0.7874 (z = -0.34, r = 0.21). Freesurfer performed slightly better in terms of classification accuracy, both on cross sectional and longitudinal analyses.

Discussion

This study could be considered as a first attempt to verify the mutual strengths and weaknesses of Civet and Freesurfer in a real head-to-head challenge, at the precision level of the single voxel. In the literature, only phantom-based validation methods have been used [27,28] but this kind of approach does not take into consideration every aspects of real data. We investigated and compared the performances of Civet and Freesurfer when applied to the same ADNI1...
Fig 3. Longitudinal comparison. A) Absolute difference maps (mm) in each group. In CTR and sMCI, both pipelines report a very mild and widespread cortical thinning rate in the motor, somatosensory, verbal and visual association cortex. In pMCI, the atrophy peaks at rates around 0.3 mm in the medial temporal cortex, temporal-parietal-frontal neocortices, with sparing of the sensorimotor strip and of the visual cortex. In AD, the atrophy in the same areas accelerates beyond 0.4 mm. B) Disease effect maps. The mean estimate of the longitudinal disease effect in CTR and sMCI as computed by Freesurfer is greater, although Civet shows higher results in few scattered areas. Furthermore, in the entire disease spectrum, Freesurfer exhibited higher disease effect in the motor cortex. In pMCI, Civet exhibits a greater disease effect except for the cingulate gyrus, while in the AD group the exception is represented by the precuneus. C) Statistical difference maps (p<0.01 FDR-corrected). In CTR, Civet detects an atrophic cluster in the angular gyrus; while Freesurfer in the precuneus and in the temporo-occipital lobe. The pattern in sMCI was more reduced than in CTR. In pMCI Freesurfer was not able to find many regions detected by Civet with the same significance and extension (i.e.: orbital, triangular, and opercular portion of the inferior frontal gyrus, transverse-temporal and
groups which included subjects on the entire disease spectrum, as monitored in a 2-year time frame. The analyses showed commonalities and differences.

Civet and Freesurfer are characterized by specific and distinctive procedures, making it difficult to compare their outputs. This problem was solved adopting a combined approach, applying both the GVF and CPS to ensure a robust comparison of meshes characterized by different morphometry and topography completely different. Thanks to the direct vertex-by-vertex cross-algorithm comparison, the differences between the two algorithms, with regard both to cross-sectional and longitudinal analysis, were analytically mapped.

Differences between thickness evaluation of the first test (MPRAGE) and that of the retest (MPRAGE-Repeat) did not appear, suggesting high repeatability. Both Civet’s and Freesurfer’s performances changed according to the disease stage, pointing out that neither algorithm can be considered better than the other, or the best acting. Freesurfer systematically underestimated the absolute thickness by about 1 mm if compared to Civet’s performance. Explanations for this evidence are not trivial. However, the restriction of Freesurfer to 1.0 mm as resolution for the volumes to be processed could be one possible reason. Civet, relying on the volumetric Laplacian approach, can use higher resolutions (e.g. 0.8 or 0.9 mm) often adopted in ADNI1. An important role might be also played by the different mathematical procedures used by the two tools when reconstructing the gray matter sheet. Moreover, the skeleton reconstruction method adopted by Civet to build the GM sheet tends to overestimate the cortical thickness in case of blurred regions (i.e.: regions affected by noise where CSF volume is small); on the other hand, Freesurfer relies on the inner white deformation surface approach, which can be strongly influenced by the anatomical accuracy of the surface reconstruction at both inner and outer boundaries, thus giving a partially unfair anatomical accuracy of the surface reconstruction and assessment of the cortical thickness.

Cross-sectionally, both algorithms were sensitive to cortical thinning in those cortical regions heavily affected by the neuropathology. Comparing CTR to pMCI, the regions of significance found by both tool were overlapping with the those found comparing CTR and AD, albeit smaller, indicating that the differences in cortical thinning are progressive and well detectable even before a formal diagnosis of AD. This means that both tools can detect the characteristic signature of AD. Both Civet and Freesurfer were able to efficiently differentiate CTR from the AD and pMCI. All the ROIs granting such a good discrimination rate belonged to the temporal lobe. An interesting consideration for future works is the possibility to use Civet and Freesurfer to differentiate AD in particular subclasses, namely familial AD, early onset AD, and late onset AD [29,30].

Longitudinally, both pipelines showed more statistically atrophic clusters in CTR than in sMCI, but this should be considered as a confounding phenotypic effect due to demographic, numerosity, clinical and other genetic characteristics. Further analyses with a larger sample will be conducted to clarify this particular behaviour. In pMCI, Civet was able to highlight a characteristic atrophic pattern involving expected temporal areas, such as the inferior margin of central gyrus and extended lateral frontal-parietal areas, as expected. The Civet’s
### Table 4. Longitudinal ROI-based analysis.

| ROI | CIVET | FREESURFER |
|-----|-------|------------|
|     | baseline vs month24 |     |
|     | CTR | sMCI | pMCI | AD | ANOVA P-value | CTR | sMCI | pMCI | AD | ANOVA P-value |
|     | △ MEAN (mm)  |     |      |     |       |

1. **Frontal**
   - Superior Frontal Gyrus, pars triangularis
     - CTR: -0.03, 0.06, 0.10, 0.11
     - sMCI: -0.10, 0.12
     - pMCI: -0.13, 0.12
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Middle Frontal Gyrus
     - CTR: -0.03, 0.06, 0.10, 0.11
     - sMCI: -0.10, 0.12
     - pMCI: -0.13, 0.12
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Inferior Frontal Gyrus, pars opercularis
     - CTR: -0.02, 0.07, 0.10, 0.11
     - sMCI: -0.10, 0.12
     - pMCI: -0.14, 0.12
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Frontal Orbital Cortex
     - CTR: -0.03, 0.09, 0.06, 0.11
     - sMCI: -0.09, 0.10
     - pMCI: -0.11, 0.10
     - AD: <0.0001
     - ANOVA P-value: <0.0001

2. **Parietal**
   - Superior Parietal Lobule
     - CTR: -0.03, 0.06, 0.09, 0.10
     - sMCI: -0.09, 0.10
     - pMCI: -0.11, 0.10
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Supramarginal Gyrus, anterior division
     - CTR: -0.03, 0.06, 0.09, 0.10
     - sMCI: -0.09, 0.10
     - pMCI: -0.11, 0.10
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Precuneus Cortex
     - CTR: -0.01, 0.06, 0.07, 0.11
     - sMCI: -0.07, 0.11
     - pMCI: -0.11, 0.11
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Lateral Occipital Cortex, superior division
     - CTR: -0.03, 0.06, 0.09, 0.10
     - sMCI: -0.09, 0.10
     - pMCI: -0.11, 0.10
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Lateral Occipital Cortex, inferior division
     - CTR: -0.03, 0.06, 0.09, 0.10
     - sMCI: -0.09, 0.10
     - pMCI: -0.11, 0.10
     - AD: <0.0001
     - ANOVA P-value: <0.0001

3. **Temporal**
   - Temporal Pole
     - CTR: -0.04, 0.11, 0.15, 0.20
     - sMCI: -0.17, 0.21
     - pMCI: -0.29, 0.32
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Superior Temporal Gyrus, anterior division
     - CTR: -0.03, 0.07, 0.11, 0.16
     - sMCI: -0.10, 0.16
     - pMCI: -0.16, 0.16
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Superior Temporal Gyrus, posterior division
     - CTR: -0.04, 0.08, 0.11, 0.16
     - sMCI: -0.11, 0.16
     - pMCI: -0.16, 0.16
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Middle Temporal Gyrus, anterior division
     - CTR: -0.03, 0.06, 0.13, 0.18
     - sMCI: -0.13, 0.18
     - pMCI: -0.21, 0.15
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Middle Temporal Gyrus, posterior division
     - CTR: -0.04, 0.06, 0.12, 0.19
     - sMCI: -0.15, 0.19
     - pMCI: -0.20, 0.12
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Middle Temporal Gyrus, temporo-occipital part
     - CTR: -0.04, 0.06, 0.10, 0.16
     - sMCI: -0.12, 0.16
     - pMCI: -0.16, 0.11
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Inferior Temporal Gyrus, anterior division
     - CTR: -0.02, 0.08, 0.13, 0.18
     - sMCI: -0.13, 0.18
     - pMCI: -0.21, 0.15
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Inferior Temporal Gyrus, posterior division
     - CTR: -0.03, 0.09, 0.13, 0.18
     - sMCI: -0.15, 0.18
     - pMCI: -0.18, 0.18
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Inferior Temporal Gyrus, temporo-occipital part
     - CTR: -0.02, 0.09, 0.10, 0.15
     - sMCI: -0.14, 0.16
     - pMCI: -0.16, 0.16
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Parahippocampal Gyrus, anterior division
     - CTR: -0.04, 0.06, 0.09, 0.11
     - sMCI: -0.14, 0.16
     - pMCI: -0.16, 0.16
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Parahippocampal Gyrus, posterior division
     - CTR: -0.03, 0.06, 0.09, 0.11
     - sMCI: -0.14, 0.16
     - pMCI: -0.16, 0.16
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Temporal Fusiform Cortex, anterior division
     - CTR: -0.02, 0.05, 0.15, 0.18
     - sMCI: -0.12, 0.18
     - pMCI: -0.20, 0.16
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Temporal Fusiform Cortex, posterior division
     - CTR: -0.02, 0.05, 0.15, 0.18
     - sMCI: -0.12, 0.18
     - pMCI: -0.20, 0.16
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Hesch’s Gyrus (includes H1 and H2)
     - CTR: -0.05, 0.07, 0.11, 0.13
     - sMCI: -0.10, 0.15
     - pMCI: -0.12, 0.15
     - AD: <0.0001
     - ANOVA P-value: <0.0001
   - Temporal Planum
     - CTR: -0.05, 0.06, 0.05, 0.11
     - sMCI: -0.10, 0.15
     - pMCI: -0.12, 0.15
     - AD: <0.0001
     - ANOVA P-value: <0.0001

**Longitudinal average cortical thinning differences (mm), standard deviation (σ), and Tukey-Kramer multiple comparison post-hoc analysis in ANOVA (P).** The data refer to: (d) CTR, (e) sMCI, (f) pMCI and (g) AD; α = 0.01 level.

≥: Significant difference between CTR and pMCI;
¥: Significant difference between CTR and AD.
Ξ: Significant difference between sMCI and pMCI;
*: Significant difference between sMCI and AD N.S.; Not significant; CTR: Normal elderly controls; sMCI: stable MCI; pMCI: progressive MCI; AD: Alzheimer's disease.

doi:10.1371/journal.pone.0117692.t004
Fig 4. Hedges’ g effect size graphs in the different ROI areas. The first two panels represent the cross-sectional effect sizes comparing the overall trend of CTR versus pMCI, and of CTR versus AD. The remaining three panels represent the longitudinal effect sizes between the baseline and month 24 in CTR, pMCI, and AD groups. The * symbol stands for $p < 0.05$. 

doi:10.1371/journal.pone.0117692.g004
In the CTR group, no significant differences between ROIs were detected in the two pipelines at BSL. At M24, significant differences between the two pipelines were found in the: middle frontal gyrus; inferior frontal gyrus—pars triangularis; superior parietal lobule; anterior division of the supramarginal gyrus; anterior and posterior division of the superior temporal gyrus. Longitudinally, no significant differences between ROIs were detected.
higher effect size and its more representative cortical signature suggest that this tool can detect the typical atrophic patterns in subject that will convert to AD within 2 years more efficiently. In the discriminant analysis, Civet produced an AUC slightly lower than that produced by Freesurfer; but this was probably due to random noises that confuses classifiers, producing changes hard to predict and control. Additional explanation can be related to the fact that longitudinally, on a vertex-by-vertex basis, Civet showed a more extensive effect than Freesurfer, while on a ROI basis the differences between the pipelines were not significant. In the AD cohort both Freesurfer and Civet were analogously sensitive to the thinning
patterns. As far as the correlation between the cortical thinning and hippocampal atrophic rate is concerned, Freesurfer showed a better trend, probably due to the exploitation of the longitudinal stream.

Given its progressive alteration along the MCI-to-AD course, cortical thickness seems to be a promising neuroimaging candidate marker. With few exceptions, the two algorithms showed robust multi-ROI correlation patterns fairly consistent with the usual clinical and regional neuroimaging biomarkers, thus producing new, 3D, global profiles of the disease progression.

Ultimately, having reliable 3D diagnostic markers would enable clinicians to identify and treat MCI patients who will evolve into AD patients in a timely manner, as disease-modifying treatments will become available.

Future studies, including the MR 3.0 Tesla field strength, additional time points, extended age range of subject, larger and additional groups, might be helpful to further address the spatial and temporal atrophic pattern of the Alzheimer’s changes.

Freesurfer and Civet have been validated against either histological analysis or manual measurements [31–34], but none of them has been contrasted against different stages of the Alzheimer’s pathology. Future works should focus on further validating both pipelines against a database of cortical thickness derived from a population of normal and abnormal cadaveric brains, such as those recently defined in the BigBrain initiative (https://bigbrain.loris.ca/).

Some limitations should be considered in the interpretation of the present results. First, the tools here described need to be further compared with other recent available techniques, such as: Toads-Cruise [35], ARCTIC [36], MILXCTE [37], DiReCT [38], or CLADA [39]. Second, as expert manual rater in neuroimaging represents the gold standard, independent evaluators should compare the performance and accuracy of each automatic pipeline. Third, each tool should be validated against harmonized MR datasets, such as: standardized ADNI analysis dataset [40], WW-ADNI [41], AddNeuroMed [42] and OASIS [43]. Fourth, computational time is worth consideration: the extensive use of Civet or Freesurfer to analyse large volumes of data mandatorily requires HPC, Grid or Cloud resources, due to the protracted processing time needed. Additional developing and programming can make these algorithms more reliable, faster and slighter.

**Conclusion**

Both Civet and Freesurfer demonstrated high sensitivity to cortical gray matter changes cross-sectionally and longitudinally. Additional efforts are needed to clarify the ability of these tools to address particular clinical and research questions concerning the future use of cortical thickness as a biomarker, and in particular their ability to: (I) predict cortical decline along different time points, (II) reduce the number of patients needed for future clinical trials, (III) help monitoring the efficacy of disease modifying drugs.

**Supporting Information**

S1 Fig. Flowchart of the study methodology. (TIF)

S2 Fig. Civet and Freesurfer B2B repeatability. (TIF)

S3 Fig. Freesurfer and Civet absolute cortical thickness maps for every diagnostic class. (TIF)
S1 Table. List of subjects’ RIDs.

S2 Table. Whole brain absolute mean cortical thickness (mm) ± standard deviation (σ) for each diagnostic group at baseline and month 24.

S3 Table. Cross-sectional thinning percentages (%) ± standard deviation (σ) in paired diagnostic groups at baseline.

S4 Table. Longitudinal thinning percentage (%) ± standard deviation (σ) in each diagnostic group in a time span of two years.

Acknowledgments

The authors thank all the partners in FP7 neuGRID (i.e., Provincia Lombardo Veneta Ordine Ospedaliero di San Giovanni di Dio Fatebenefratelli: Alberto Redolfi, Gabriele Corbetta; Paolo Bosco; Cristina Bagnoli; Libera Virginia Cavaliere; Gnúbila France: David Manset; Jerome Revillard; Baptiste Grenier; University of the West of England: Richard McClatchey; Andrew Branson; Kamran Munir; Jetendr Shamdasani; Saad Liaquat; VU University Medical Center Amsterdam: Frederik Barkhof; Keith S Cover; Bob van Dijk; Ronald van Schijndel; Adriaan Versteeg; Karolinska Institutet: Wahlund Lars-Olof; Gabriela Spulber; Örndahl Eva; CF consulting: Carla Finocchiaro; NeuroSpin-CEA: Jean-François Mangin; Jean-Baptiste Poline; Edouard Duchesnay; Vincent Frouin; Yann Cointepas; University of Southern California: Arthur Toga; McGill University: Alan Evans; Marc-Etienne Rousseau; CNRS: Vincent Breton; Genevieve Romier; Hôpitaux Universitaires de Genève: Luigi Antelmi, and Principal Investigator: Giovanni B Frisoni, (gfrisoni@fatebenefratelli.it)) for the support and provision of computing resources. The resources used in VIP are operated and provided by the European Grid Infrastructure (http://www.egi.eu) to the “biomed” Virtual Organization. Special thanks go to Assistant Professor Jonathan Wisco, UCLA, Department of Pathology and Laboratory Medicine, Los Angeles, USA. Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. Thanks to Chiara Barattieri di San Pietro for editing the manuscript.

Disclaimer: Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI
investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgment_List.pdf

Author Contributions
Conceived and designed the experiments: AR FB LOW GBF. Performed the experiments: AR DM TG. Analyzed the data: AR FB LOW JFM GBF. Contributed reagents/materials/analysis tools: AR DM FB LOW TG JFM GBF. Wrote the paper: AR DM FB LOW TG JFM GBF. Data exposure and storage in neuGRID: AR DM JFM GBF.

References
1. Fox NC, Kennedy J (2009) Structural imaging markers for therapeutic trials in Alzheimer’s disease. J Nutr 13(4): 350–352.
2. Jack CR Jr, Shiung MM, Gunter JL, O’Brien PC, Weigand SD, et al. (2004) Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 62(4): 591–600. PMID: 14981176
3. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, et al. (2005) Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64(9): 1563–1572. PMID: 15883317
4. Thompson P, Hayashi KM, Zubicaray G, Janke AL, Rose SE, et al. (2003) Dynamics of gray matter loss in Alzheimer’s disease. J Neurosci 23: 994–1005. PMID: 12574429
5. Han X, Jovicich J, Salat D, van der Kouwe A, Quinn B, et al. (2006) Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. Neuroimage 32(1): 180–94. PMID: 16651008
6. Dickerson BC, Sperling RA (2005) Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer’s disease. NeuroRx 2: 348–360. PMID: 15897955
7. MacDonald D, Kabani N, Avis D, Evans AC (2000) Automated 3-D extraction of inner and outer surfaces of cerebral cortex from MRI. Neuroimage 12(3): 340–356. PMID: 10944416
8. Fischl B, Dale AM (2000) Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A 97(20): 11050–11055. PMID: 10984517
9. Dahnke R, Yotter RA, Gaser C (2013) Cortical thickness and central surface estimation. Neuroimage 65:336–48. doi: 10.1016/j.neuroimage.2012.09.050 PMID: 23041529
10. Kim JS, Singh V, Lee JK, Lerch J, Ad-Otab’bagh Y, et al. (2005) Automated 3-D extraction and evaluation of the inner and outer cortical surfaces using a laplacian map and partial volume effect classification. Neuroimage 27(1): 210–221. PMID: 15896981
11. Dale AM, Fischl B, Sereno MI (1999) Cortical surface-based analysis. I. segmentation and surface reconstruction. Neuroimage 9(2): 179–194. PMID: 9931268
12. Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM (2010) The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6(2): 67–77. doi: 10.1038/nrneurol.2009.215 PMID: 20139996
13. Clarkson MJ, Cardoso MJ, Ridgway GR, Modat M, Leung KK, et al. (2011) A comparison of voxel and surface based cortical thickness estimation methods. Neuroimage 57(3): 856–865. doi: 10.1016/j.neuroimage.2011.05.053 PMID: 21640841
14. Redolfi A, Bosco P, Manset D, Frisoni GB; neuGRID consortium (2013) Brain investigation and brain conceptualization. Funct Neurol 28(3): 175–190. doi: 10.1138/FNeur/2013.28.3.175 PMID: 24199654
15. Glatard T, Lartizien C, Gibaud B, da Silva RF, Forestier G, et al. (2013) A virtual imaging platform for multi-modality medical image simulation. IEEE Trans Med Imaging 32(1): 110–118. PMID: 23014715
16. Reuter M, Schmansky NJ, Rosas HD, Fischl B (2012) Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 61(4): 1402–1418. doi: 10.1016/j.neuroimage.2012.02.084 PMID: 22430496
17. Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, et al. (2006) An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 31(3): 968–980. PMID: 16530430
18. Dickerson BC, Feczko E, Augustinack JC, Pacheco J, Morris JC, et al. (2009a) Differential effects of aging and Alzheimer’s disease on medial temporal lobe cortical thickness and surface area. Neurobiol Aging 30(3): 432–440. PMID: 17869384
19. Dickerson BC, Bakkour A, Salat DH, Feczek E, Pacheco J, et al. (2009b) The cortical signature of Alzheimer’s disease: Regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 19(3): 497–510. doi: 10.1093/cercor/bhn113 PMID: 18632739

20. Liu T, Nie J, Tarokh A, Guo L, Wong ST (2008) Reconstruction of central cortical surface from brain MRI images: Method and application. Neuroimage 40(3): 991–1002. doi: 10.1016/j.neuroimage.2007.12.027 PMID: 18298979

21. Querbes O, Aubry F, Parisote J, Lotterie JA, Démonet JF, et al. (2009) Early diagnosis of Alzheimer’s disease using cortical thickness: Impact of cognitive reserve. Brain 132: 2036–2047. doi: 10.1093/brain/awp105 PMID: 19439419

22. Genovese CR, Lazar NA, Nichols T (2002) Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage 15(4): 870–878. PMID: 11906227

23. Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148(3): 839–843. PMID: 6878078

24. Lerch JP, Evans AC (2005) Cortical thickness analysis examined through power analysis and a population simulation. Neuroimage 24(1): 163–173. PMID: 15588607

25. Jones R, Payne R (1997) Clinical Investigation and Statistics in Laboratory Medicine (Management & Technology in Laboratory Medicine). ACB Venture Publications. 188 p. ISBN-10: 0902429213. ISBN-13: 978–0902429215.

26. Brewer JB, Magda S, Airriess C, Smith ME (2009) Fully-automated quantification of regional brain volumes for improved detection of focal atrophy in Alzheimer Disease. Am J Neuroradiol 30(3): 578–580. doi: 10.3174/ajnr.A1402 PMID: 19112065

27. Lee JK, Lee JM, Kim JS, Kim IY, Evans AC, et al. (2006a) A novel quantitative cross-validation of different cortical surface reconstruction algorithms using MRI phantom. Neuroimage 31(2): 572–584.

28. Lee J, Lee JM, Kim JH, Kim IY, Evans AC, et al. (2006b) A novel quantitative validation of the cortical surface reconstruction algorithm using MRI phantom: issues on local geometric accuracy and cortical thickness. Med Image Comput Comput Assist Interv 9: 183–190. PMID: 17354889

29. Knight WD, Kim LG, Douiri A, Frost C, Rossor MN, et al. (2011) Acceleration of cortical thinning in familial Alzheimer’s disease. Neurobiol Aging 32(10): 1765–1773. doi: 10.1016/j.neurobiolaging.2009.11.013 PMID: 20005601

30. Ridgway GR, Lehmann M, Barnes J, Rohrer JD, Warren JD, et al. (2012) Early-onset Alzheimer disease clinical variants: multivariate analyses of cortical thickness. Neurology 79(1): 80–84. doi: 10.1212/WNL.0b013e31825dce28 PMID: 22722624

31. Kabani N, Le Goualher G, MacDonald D, Evans AC (2001) Measurement of cortical thickness using an automated 3-D algorithm: A validation study. Neuroimage 13(2): 375–380. PMID: 11162277

32. Kuperberg GR, Broome MR, McGuire PK, David AS, Eddy M, et al. (2003) Regionally localized thinning of the cerebral cortex in schizophrenia. Arch Gen Psychiatry 60(9): 878–888. PMID: 12963699

33. Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, et al. (2002) Regional and progressive thinning of the cortical ribbon in Huntington’s disease. Neurology 58(5): 695–701. PMID: 11889230

34. Salat DH, Buckner RL, Snyder AZ, Greve DN, Desikan RS, et al. (2004) Thinning of the cerebral cortex in aging. Cereb Cortex 14(7): 721–730. PMID: 15054051

35. Han X, Pham DL, Tosun D, Rettmann ME, Xu C, et al. (2004) CRUISE: Cortical reconstruction using implicit surface evolution. Neuroimage 23(3): 997–1012. PMID: 15528100

36. Hazlett HC, Poe MD, Gerig G, Styner M, Chappell C, et al. (2011) Early brain overgrowth in autism associated with an increase in cortical surface area before age 2 years. Arch Gen Psychiatry 68(5): 467–476. doi: 10.1001/archgenpsychiatry.2011.39 PMID: 21936976

37. Acosta O, Fripp J, Doré V, Bourgeat P, Favreau JM, et al. (2012) Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer’s disease. J Neurosci Methods 205(1): 96–109. doi: 10.1016/j.jneumeth.2011.12.011 PMID: 22226742

38. Das SR, Avants BB, Grossman M, Gee JC (2009) Registration based cortical thickness measurement. Neuroimage 45: 867–879. doi: 10.1016/j.neuroimage.2008.12.016 PMID: 19150502

39. Nakamura K, Fox R, Fisher E (2011) CLADA: Cortical longitudinal atrophy detection algorithm. Neuroimage 54(1): 278–289. doi: 10.1016/j.neuroimage.2010.07.052 PMID: 20674750

40. Wyman BT, Harvey DJ, Crawford K, Bernstein MA, Carmichael O, et al. (2013) Standardization of analysis sets for reporting results from ADNI MRI data. Alzheimers Dement 9(3):332–7. doi: 10.1016/j.jalz.2012.06.004 PMID: 23110865
41. Carrillo MC, Bain LJ, Frisoni GB, Weiner MW (2012) Worldwide Alzheimer’s disease neuroimaging initiative. Alzheimers Dement 8(4): 337–342. doi:10.1016/j.jalz.2012.04.007 PMID: 22748939

42. Westman E, Simmons A, Muehlboeck JS, Mecocci P, Vellas B, et al. (2011) AddNeuroMed and ADNI: similar patterns of Alzheimer’s atrophy and automated MRI classification accuracy in Europe and North America. Neuroimage 58(3): 818–828. doi:10.1016/j.neuroimage.2011.06.065 PMID: 21763442

43. Ardekani BA, Figarsky K, Sidtis JJ (2013) Sexual Dimorphism in the Human Corpus Callosum: An MRI Study Using the OASIS Brain Database. Cereb Cortex 23(10): 2514–2520. doi:10.1093/cercor/bhs253 PMID: 22891036